DR. MICHAEL ANATOL NORCROSS, M.D.
Medical Practice at Cordell Ave, Bethesda, MD
License number
Maryland MD16403
Category
Medical Practice
Type
Public Health & General Preventive Medicine
Address
Address
4853 Cordell Ave, Bethesda, MD 20814
Phone
(301) 728-8709
Professional information
Michael Anatol Norcross, Bethesda MD
Specialties:
Preventive Medicine Specialist
Address:
4853 Cordell Ave, Bethesda, MD 20814
Dr. Michael A Norcross, Bethesda MD - MD (Doctor of Medicine)
Specialties:
Anatomic & Clinical Pathology
Address:
4853 Cordell Ave STE 821, Bethesda 20814
(301) 728-8709 (Phone)
(301) 728-8709 (Phone)
Languages:
English
Education:
Medical School
University of Florida
Graduated: 1976
University of Florida
Graduated: 1976
Chemokine Variants
US Patent:
6534626, Mar 18, 2003
Filed:
Sep 14, 2000
Appl. No.:
09/555663
Inventors:
Tamas Oravecz - Palo Alto CA
Michael A. Norcross - Bethesda MD
Michael A. Norcross - Bethesda MD
Assignee:
The United States of America as represented by the Department of Health Human Services - Washington DC
International Classification:
C07K 500
US Classification:
530300, 500324, 4353201, 435 911, 536 231, 536 2433
Abstract:
The present invention provide the nucleotide and amino acid sequence of truncated RANTES (3-68) which has the same amino acid sequence as the wild-type RANTES, but with a serine/proline truncation at positions 1 and 2 from the N-terminus, respectively.
Chemokine Variants And Methods Of Use
US Patent:
2003022, Dec 11, 2003
Filed:
Mar 18, 2003
Appl. No.:
10/392355
Inventors:
Tamas Oravecz - Palo Alto CA, US
Michael Norcross - Bethesda MD, US
Michael Norcross - Bethesda MD, US
International Classification:
C07K014/715, C07H021/04, C12P021/02, C12N005/06
US Classification:
530/350000, 536/023500, 435/069100, 435/320100, 435/325000
Abstract:
The present invention provides the nucleotide and amino acid sequence of truncated RANTES (3-68), which has the same amino acid sequence as the wild-type RANTES, but with a Serine/Proline truncation at positions 1 and 2 from the N-terminus, respectively. CD26 is a leukocyte activation marker that possesses dipeptidyl peptidase IV (DPPIV) activity but whose natural substrates and immunological functions had not been previously defined. Several chemokines, including RANTES (regulated on activation, normal T expressed and secreted) are provided, which are substrates for human CD26. The truncated RANTES (3-68) lacked the ability of native RANTES (1-68) to increase the cytosolic calcium concentration in human monocytes, but it still induces this response in macrophages activated with macrophage colony-stimulating factor (M-CSF). RANTES (3-68) retains the ability to stimulate CCR5 receptors and to inhibit the cytopathic effects of HIV-1. The invention provides methods for identifying compounds that affect DPPIV-medicated chemokine cleavage, methods for inhibiting HIV infection and treating individuals having or at risk of having HIV infection, methods for diagnosis and/or prognosis of individuals having a chemokine-associated disorder and methods for accelerating wound healing and angiogenesis, all based on the discovery of DPPIV-mediated cleavage of chemokines.
Use Of Hiv Envelope/Cd4 Complexes For The Generation Antibodies
US Patent:
2009021, Aug 27, 2009
Filed:
Aug 25, 2006
Appl. No.:
11/990953
Inventors:
Jinhai Wang - Gaithersburg MD, US
Michael Norcross - Bethesda MD, US
Michael Norcross - Bethesda MD, US
Assignee:
Government of the US, as represented by the Secretary, Dept. of Health & Human Services - Rockville MD
International Classification:
A61K 39/21, C07K 16/18, C12N 5/00
US Classification:
4241601, 5303879, 435325, 4242081
Abstract:
The instant invention provides antibodies, vaccines, and immunogenic compositions, for the treatment and prevention of HIV infection. The invention further provides kits comprising the antibodies, vaccines and immunogenic compositions, of the invention.